Analysis of the influence of hormone replacement therapy on TNF-alpha serum levels in menopausal women

Rahnama, Mansur; Jamrogiewicz, Izabela; Jamrogiewicz, Rafał

doi:10.5604/17322693.1024788

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-osteoporotic effects of other agents have also been shown related to decline in the circulating levels of TNF-a during therapy. [1131] The decline of the mean serum TNF-α levels from 12.04 ± 2.81 pg/ml at baseline to 2.35 ± 1.08 pg/ml at the end of the study was statistically significant. The effect suggests a decline in osteoclastogenesis and as a consequence, a putative stabilization of BMD or its increase.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

A clinical study of a standardized extract of leaves of Dalbergia sissoo (Roxb ex DC) in postmenopausal osteoporosis

et al. 2019

View full text Add to dashboard Cite

Context: Dalbergia sissoo had shown anti-osteoporotic and fracture-healing activities in animal models of postmenopausal osteoporosis (PMO). Standardized extract of leaves of D. sissoo (SEL-Ds) was clinically evaluated for osteoporosis. Aims: To investigate the anti-osteoporotic activity of D. sissoo in PMO by dual-energy X-ray absorptiometry (DXA), biochemical markers, and effect on clinical profile. Tolerability was assessed by organ function tests and adverse events. Settings and Design: An open-labeled prospective clinical study in ambulant settings was conducted at the menopausal health-care facility of a women's hospital. Materials and Methods: Thirty women (45–69 years) were enrolled for this 1-year study. Evaluations were basally, fortnightly twice, and three monthly four times. SEL-Ds (300 mg) twice daily was administered orally. Calcium (250 mg) and Vitamin D (200 IU) were given twice a day. The efficacy of SEL-Ds was assessed by DXA-scan (spine, femur), by biochemical markers, alkaline phosphatase (ALP), tumor necrosis factor-alpha (TNF-α), and anti-inflammatory marker high-sensitivity C-reactive protein (hs-CRP). Baseline symptom changes and adverse events were carefully recorded. Statistical Analysis: Summary statistics (n, mean, standard deviation, median, and maximum and minimum values) of changes from baseline values and Student's “t-” test for P values were used. Results and Discussion: SEL-Ds was well tolerated at given dose for 1 year. Anti-osteoporotic and anti-inflammatory activities of SEL-Ds were demonstrated by reduction in TNF-α (12.04 ± 2.81–2.35 ± 1.08 pg/ml), ALP (208.75 ± 45.88–154.52 ± 37.25 IU/L), and hs-CRP (6.1 ± 0.77–3.9 ± 0.47 mg/L). BMD-score on DXA-scan also remained unchanged at majority of the bone locations (increased 13/75, unchanged 51/75, and decreased 08/75). Conclusions: D. sissoo has demonstrated anti-osteoporotic and anti-inflammatory activities as indicated by decline in circulating TNF-α along with concurrent reduction in ALP. The nondecline in BMD index in the majority confirms the anti-osteoporotic activity.

show abstract

Section: Discussionmentioning

confidence: 93%

“…[910] Decrease in the serum TNF-α levels in postmenopausal women during hormone replacement therapy (HRT) has been reported. [11] HRT, till Women's Health Initiative (WHI) outcome in 2002, provided an excellent preventive and therapeutic modality for PMO. However, since then, a paradigm shift has occurred.…”

Section: Introductionmentioning

confidence: 99%